• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vapogenix closes $8.2m Series C for topical painkiller

December 9, 2016 By Sarah Faulkner

Vapogenix closes $8.2m Series C for topical painkillerVapogenix Inc. said yesterday that it raised $8.2 million in a Series C financing round to fund the development of its locally-acting painkiller. Pamoja Capital and a group of pain physicians led the round.

The Houston, Texas-based company’s technology is a topical formulation of volatile anesthetics, which are normally inhaled as general anesthesia. Vapogenix has developed volatile anesthetic-based topical gels and liquids to treat wounds, combat-related injuries, osteoarthritis, and muscular and inflammatory conditions. The funding will support a phase II proof-of-concept study of the topical painkiller, which Vapogenix anticipates will begin next year.

“There is enormous potential and demand for a safe, pain-relief therapy that treats wounds and burns at the source of the pain.  The topical delivery of Vapogenix medicines will help minimize the need for, and the numerous side-effects of, systemic drugs like opioids,” co-founder & CEO Danguole Altman said in prepared remarks. “Overdoses involving opioids killed more than 28,000 people in 2014 and more than half of those deaths were from prescription opioids.  This horrific epidemic demands that we find better, more innovative solutions to pain management.”

“This is groundbreaking work in that this is the first time volatile anesthetics have been formulated to treat pain topically,” co-founder and scientific advisory board chairman Dr.Allen Burton added. “Extensive case reports support dramatic pain reduction, rapid onset and localized effect of Project AWARD.  We are thrilled to begin a phase II proof-of-concept study as this is an important step towards commercialization of this product.”

Filed Under: Featured, Funding Roundup, Pain Management, Preclinical Trials Tagged With: Vapogenix Inc.

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS